Literature DB >> 26850638

Identification of Inhibitors of Pseudomonas aeruginosa Exotoxin-S ADP-Ribosyltransferase Activity.

Ana Filipa Pinto1, Mahsa Ebrahimi1, Michael Saleeb2, Åke Forsberg3, Mikael Elofsson2, Herwig Schüler4.   

Abstract

The gram-negative bacterium Pseudomonas aeruginosa is an opportunistic pathogen associated with drug resistance complications and, as such, an important object for drug discovery efforts. One attractive target for development of therapeutics is the ADP-ribosyltransferase Exotoxin-S (ExoS), an early effector of the type III secretion system that is delivered into host cells to affect their transcription pattern and cytoskeletal dynamics. The purpose of this study was to formulate a real-time assay of purified recombinant ExoS activity for high-throughput application. We characterized the turnover kinetics of the fluorescent dinucleotide 1,N(6)-etheno-NAD+ as co-substrate for ExoS. Further, we found that the toxin relied on any of five tested isoforms of human 14-3-3 to modify vH-Ras and the Rho-family GTPases Rac1, -2, and -3 and RhoC. We then used 14-3-3β-stimulated ExoS modification of vH-Ras to screen a collection of low-molecular-weight compounds selected to target the poly-ADP ribose polymerase family and identified 3-(4-oxo-3,5,6,7-tetrahydro-4H-cyclopenta[4,5]thieno[2,3-d]pyrimidin-2-yl)propanoic acid as an ExoS inhibitor with micromolar potency. Thus, we present an optimized method to screen for inhibitors of ExoS activity that is amenable to high-throughput format and an intermediate affinity inhibitor that can serve both as assay control and as a starting point for further development.
© 2016 Society for Laboratory Automation and Screening.

Entities:  

Keywords:  ADP-ribosylation; Pseudomonas aeruginosa; bacterial toxins; drug discovery; enzyme inhibitors

Mesh:

Substances:

Year:  2016        PMID: 26850638     DOI: 10.1177/1087057116629923

Source DB:  PubMed          Journal:  J Biomol Screen        ISSN: 1087-0571


  3 in total

1.  Beyond Antibiotics: New Therapeutic Approaches for Bacterial Infections.

Authors:  Alan R Hauser; Joan Mecsas; Donald T Moir
Journal:  Clin Infect Dis       Date:  2016-03-29       Impact factor: 9.079

2.  Pseudomonas aeruginosa Antivirulence Strategies: Targeting the Type III Secretion System.

Authors:  Joanna B Goldberg; Cristian V Crisan; Justin M Luu
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 3.650

3.  14-3-3 proteins activate Pseudomonas exotoxins-S and -T by chaperoning a hydrophobic surface.

Authors:  Tobias Karlberg; Peter Hornyak; Ana Filipa Pinto; Stefina Milanova; Mahsa Ebrahimi; Mikael Lindberg; Nikolai Püllen; Axel Nordström; Elinor Löverli; Rémi Caraballo; Emily V Wong; Katja Näreoja; Ann-Gerd Thorsell; Mikael Elofsson; Enrique M De La Cruz; Camilla Björkegren; Herwig Schüler
Journal:  Nat Commun       Date:  2018-09-17       Impact factor: 14.919

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.